Osivax is a Franco‑Belgian, Lyon‑based biotech with about 50 employees developing OVX836, a broad‑spectrum influenza A vaccine candidate. The company aims to advance OVX836 through clinical trials, prepare large‑scale efficacy studies, and scale up production. It has a longer‑term ambition to develop a pan‑respiratory vaccine that would protect in a single injection against all influenza strains and all COVID‑19 variants. Osivax secured a $19.5 million (€18 million) multi‑year funding award from BARDA to accelerate development of OVX836. The support will cover continuation of clinical trials, preparation of large‑scale efficacy studies, and manufacturing ramp‑up. In March the company raised €10 million in its first Series B financing. Osivax leverages its oligoDOM self-assembling nanoparticle platform to develop first-in-class pan-respiratory virus vaccines that generate strong T-cell responses alongside sustained B-cell responses. Its lead candidate, OVX836, is a broad-spectrum influenza vaccine currently in Phase 2 clinical trials, with over 1,200 volunteers tested and encouraging proof-of-concept efficacy data. The company is advancing OVX836 into a Phase 2b field efficacy study (NCT05569239) planned to enroll 2,850 participants across multiple international sites. Osivax's stated ambition is to develop a single-shot pan-respiratory vaccine preventing all strains of influenza and variants of Covid-19, and to expand into other infectious disease indications through combinations and collaborations worldwide. Financially, Osivax has completed a first close of a Series B financing, raising €10 million supplemented by non-dilutive funding to accelerate preclinical and clinical development. The company has added strategic industry expertise through a new investment from Meiji Seika Pharma to support advancement of its programs. Osivax leverages its proprietary oligoDOM® self‑assembling nanoparticle platform to generate strong T‑cell and B‑cell responses against highly mutating viruses. Its lead candidate, OVX836, targets the conserved nucleoprotein (NP) to provide broader, more universal influenza protection than surface‑antigen vaccines. OVX836 has shown promising safety, immunogenicity, and initial efficacy signals across four clinical trials, including a completed Phase 1 and Phase 2a and two ongoing Phase 2a studies, with roughly 800 subjects tested. The company plans to advance OVX836 into a large Phase 2b field efficacy trial to assess protection against a broad range of circulating strains. Osivax also intends to explore broader applications of its technology across other infectious‑disease indications via combinations and collaborations worldwide. Financially, the company recently secured non‑dilutive support to accelerate clinical development. Osivax leverages its oligoDOM® technology to develop universal vaccines for influenza and coronaviruses by targeting conserved viral antigens. The platform focuses on the nucleoprotein, a highly conserved antigen with a low mutation rate, aiming to provide lasting immunity across strains. Its lead universal flu candidate, OVX836, is in Phase 2a immunogenicity clinical development. The company is applying the same approach toward a universal coronavirus vaccine to protect against SARS‑CoV‑2 and future coronavirus strains. Public funding announced will support completion of OVX836 Phase 2a, early discovery work on the coronavirus program, and a planned large Phase 2b efficacy study. Clinical development for the coronavirus program will be run via a consortium led by Osivax with trials conducted at AP‑HP's Cochin Vaccine Evaluation Center and immune analyses by Inserm. Osivax develops universal flu vaccines built on its oligoDOM® technology, an auto-assembling, positively charged protein nanoparticle designed to present multiple copies of a conserved nucleoprotein (NP) antigen. Its lead candidate, OVX836, incorporates the natural NP from an A-strain virus and has shown efficacy and cross-protection in mouse and ferret challenge models. OVX836 was in a Phase I clinical trial with initial results expected in the second half of 2019; the company aims first for proof-of-concept in Influenza A and then to expand to a universal A/B vaccine. A second-generation candidate covering both A- and B-strains is in preclinical development. The platform is positioned to be applied to other infectious and immune system–associated diseases. Financially, Osivax has secured financing to advance clinical development and corporate growth, and has opened a subsidiary in Liège, Belgium to support its activities.

Total raised

$89M

Funding rounds

7

Latest round

Equity

Latest activity

Aug 2025